Ticker

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 46,346 shares, an increase of 2,371.8% from the February 12th total of 1,875 shares. Based on an average daily volume of

JERUSALEM, March 2, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l.

JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support.

JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd.

JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtable discussion organized by the Manufacturers Association of Israel during…